These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31296652)

  • 1. Correction:
    Ann Rheum Dis; 2019 Aug; 78(8):e88. PubMed ID: 31296652
    [No Abstract]   [Full Text] [Related]  

  • 2. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
    Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
    Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.
    Li Z; Xu D; Jiang X; Li T; Su Y; Mu R
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term organ damage accrual and late mortality in systemic sclerosis.
    Lazzaroni MG; Moschetti L; Breda M; Franceschini F; Airò P
    Clin Exp Rheumatol; 2023 Oct; ():. PubMed ID: 37933549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
    Ross L; Hansen D; Proudman S; Khanna D; Herrick AL; Stevens W; ; ; Baron M; Nikpour M;
    Arthritis Rheumatol; 2024 Jun; ():. PubMed ID: 38937146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.
    Baron M; Kahaleh B; Bernstein EJ; Chung L; Clements PJ; Denton C; Domsic RT; Ferdowsi N; Foeldvari I; Frech T; Gordon JK; Hudson M; Johnson SR; Khanna D; McMahan Z; Merkel PA; Narain S; Nikpour M; Pauling JD; Ross L; Valenzuela Vergara AM; Vacca A
    J Scleroderma Relat Disord; 2019 Feb; 4(1):17-27. PubMed ID: 30906878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
    Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome measurements in scleroderma: results from a delphi exercise.
    Gazi H; Pope JE; Clements P; Medsger TA; Martin RW; Merkel PA; Kahaleh B; Wollheim FA; Baron M; Csuka ME; Emery P; Belch JF; Hayat S; Lally EV; Korn JH; Czirjak L; Herrick A; Voskuyl AE; Bruehlmann P; Inanc M; Furst DE; Black C; Ellman MH; Moreland LW; Rothfield NF; Hsu V; Mayes M; McKown KM; Krieg T; Siebold JR
    J Rheumatol; 2007 Mar; 34(3):501-9. PubMed ID: 17299843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).
    Pope J
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S98-111. PubMed ID: 22588774
    [No Abstract]   [Full Text] [Related]  

  • 13. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
    Khanna D; Lovell DJ; Giannini E; Clements PJ; Merkel PA; Seibold JR; Matucci-Cerinic M; Denton CP; Mayes MD; Steen VD; Varga J; Furst DE;
    Ann Rheum Dis; 2008 May; 67(5):703-9. PubMed ID: 17893248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study.
    Valenzuela A; Baron M; ; Herrick AL; Proudman S; Stevens W; ; Rodriguez-Reyna TS; Vacca A; Medsger TA; Hinchcliff M; Hsu V; Wu JY; Fiorentino D; Chung L
    Semin Arthritis Rheum; 2016 Dec; 46(3):344-349. PubMed ID: 27371996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Gorga M; Mihai C; Soare AM; Dobrotă R; Gherghe AM; Stoica V
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S61-7. PubMed ID: 26316302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial design in scleroderma: where are we and where do we go next?
    Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures of disease status in systemic sclerosis: A systematic review.
    Tay T; Ferdowsi N; Baron M; Stevens W; Hudson M; Proudman SM; Nikpour M;
    Semin Arthritis Rheum; 2017 Feb; 46(4):473-487. PubMed ID: 27765344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms.
    Tauber M; Avouac J; Benahmed A; Barbot L; Coustet B; Kahan A; Allanore Y
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-82-7. PubMed ID: 25372792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.